Abdelaziz HK, et al. - Researchers assessed clinical outcomes with aspirin for the primary prevention of cardiovascular disease following the recent publication of large trials adding more than 45,000 subjects to the published data. In this original investigators, researchers analyzed randomized, controlled trials comparing clinical outcomes with aspirin vs control for primary prevention, with follow-up of at least 1 year. All-cause mortality, cardiovascular mortality, myocardial infarction, stroke, transient ischemic attack, and major adverse cardiovascular events were the evaluated efficacy outcomes. Major bleeding, intracranial bleeding, fatal bleeding, and major gastrointestinal bleeding were included as safety outcomes. Overall, trials with 165,502 subjects (aspirin n=83,529, control n=81,973) were examined. Attenuation in nonfatal ischemic events was reported when aspirin was used for primary prevention. However, aspirin for primary prevention resulted in a significant increase in nonfatal bleeding events.